Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Prattes, J; Hoenigl, M; Rabensteiner, J; Raggam, RB; Prueller, F; Zollner-Schwetz, I; Valentin, T; Hönigl, K; Fruhwald, S; Krause, R.
Serum 1,3-beta-d-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery.
Mycoses. 2014; 57(11):679-686
Doi: 10.1111/myc.12221
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Hönigl Martin
- Prattes Jürgen
- Co-authors Med Uni Graz
- Fruhwald Sonja
- Krause Robert
- Prüller Florian
- Rabensteiner Jasmin
- Raggam Reinhard Bernd
- Valentin Thomas
- Zollner-Schwetz Ines
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The purpose of this study was to evaluate a preemptive approach with serum 1,3-beta-d-glucan (BDG) as a marker for treatment stratification of systemic antifungal (AF) therapy in patients with clinical suspected invasive fungal infections (IFI) at intensive care units (ICU), and the impact of surgical procedures. A total of 66 ICU patients with clinical suspected IFI were included in this retrospective analysis. Serum BDG testing was performed prior to initiation of AF treatment and in addition to routine diagnostic measures. Based on the BDG results the initial clinical decision whether or not to start systemic AF therapy was re-evaluated. Impact of surgical procedures on clinical utility of serum BDG was evaluated in a sub-group of 25 patients who had undergone surgical procedures prior to BDG evaluation. BDG test results led to discontinuation of AF therapy in 13 patients, and initiation of AF therapy in seven patients. In 46 patients the clinical decision was confirmed by BDG. The majority of suspected, probable and proven IFI cases (10/13, 77%) was predicted by the test. BDG testing turned out positive in 9/25 (36%) of patients that had undergone recent surgery and levels correlated with clinical findings. Serum BDG evaluation seems to be a promising tool to guide AF therapy in ICU patients even after recent surgical procedures. © 2014 Blackwell Verlag GmbH.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Antifungal Agents - therapeutic use
- Aspergillus - classification
- Aspergillus - drug effects
- Aspergillus - genetics
- Aspergillus - isolation & purification
- Candida - classification
- Candida - drug effects
- Candida - genetics
- Candida - isolation & purification
- Female -
- Humans -
- Intensive Care Units - statistics & numerical data
- Male -
- Middle Aged -
- Mycoses - blood
- Mycoses - drug therapy
- Mycoses - microbiology
- Mycoses - surgery
- Retrospective Studies -
- Young Adult -
- beta-Glucans - blood
- Find related publications in this database (Keywords)
- 1,3-Beta-D-glucan
- intensive care unit
- serum
- surgery
- antifungal therapy